Mutational dynamics between primary and relapse neuroblastomas.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Neuroblastoma is a lethal childhood cancer of the sympathetic nervous system.
• Relapse significantly reduces survival rates in neuroblastoma patients.

Purpose of the Study:

• To characterize the genetic alterations in neuroblastoma at diagnosis versus relapse.
• To understand the evolutionary genetic mechanisms driving neuroblastoma progression and treatment resistance.

Main Methods:

• Whole-exome sequencing
• mRNA expression profiling
• Array comparative genomic hybridization (CGH)
• DNA methylation analysis
• Analysis of 16 paired neuroblastoma samples (diagnosis and relapse)

Main Results:

• Relapsing tumors exhibit significantly increased mutational burden, altered mutational signatures, and reduced subclonal heterogeneity.
• Consistent patient-specific promoter methylation patterns were observed throughout disease course.
• Recurrent alterations at relapse include mutations in CHD5, chromosome 9p losses, DOCK8 mutations, PTPN14 inactivating mutations, and altered YAP activity.
• New mutations in HRAS, KRAS, and cell-cell interaction genes suggest disturbances in mesenchymal transition signaling pathways.

Conclusions:

• Genetic evolution, including increased mutation rates and selection of specific clones, drives neuroblastoma relapse.
• Alterations in signaling pathways, particularly those involved in mesenchymal transition, are critical in relapsed neuroblastoma.
• Understanding these genetic changes is crucial for developing targeted therapies for recurrent neuroblastoma.